Ovarian Cancer Clinical Trial Monitor — PARP Inhibitors, ADC & HRD Programs

The ovarian cancer trial landscape in 2026

Ovarian cancer has one of the most dynamic clinical trial landscapes in oncology, driven by the PARP inhibitor revolution and a second wave of novel mechanisms targeting the tumor microenvironment and specific molecular subtypes. With platinum-sensitive relapse representing the primary battleground, sponsors are racing to extend progression-free survival through combination strategies and novel sequencing approaches.

The ADC wave has reached ovarian cancer with multiple folate receptor alpha (FRα)-targeting programs following mirvetuximab soravtansine's approval. HER2-low expression, TROP2, and NaPi2b are all active ADC targets generating new Phase 1 and Phase 2 data in 2025–2026.

Key therapeutic areas generating new trials

PARP inhibitors: combinations and new populations

The three approved PARP inhibitors (olaparib, niraparib, rucaparib) have moved through maintenance therapy into combination strategies and earlier-line settings. Current trial activity includes:

• PARP + VEGF/VEGFR combinations in platinum-sensitive relapse
• PARP + ATR/WEE1 inhibitor combinations for PARP-resistant disease
• Next-generation PARP1-selective inhibitors (potentially reduced hematologic toxicity)
• PARP in neoadjuvant settings for high-grade serous BRCA-mutated disease
• Biomarker expansion: HRD-positive beyond BRCA mutation

Antibody-drug conjugates

Mirvetuximab soravtansine set the template for FRα-targeted ADCs in ovarian cancer. The follow-on ADC landscape includes programs with improved linker-payload designs, combination strategies with anti-VEGF therapy, and exploration of FRα-medium expression populations previously excluded from earlier studies.

Immunotherapy combinations

Single-agent checkpoint inhibitors have shown limited activity in ovarian cancer, but combination strategies continue to generate trial activity: PD-1/PD-L1 with VEGF/VEGFR inhibition, tumor-infiltrating lymphocyte therapies, and neoantigen-based vaccine approaches in immunogenic subtypes.

Clear cell and mucinous histologies

Non-serous ovarian cancers are underserved by current standard of care and are increasingly the focus of basket trials and histology-specific programs. PI3K/AKT pathway activation in clear cell carcinoma and KRAS-targeted approaches in mucinous tumors represent active areas.

Who monitors ovarian cancer clinical trials?

The professionals who need daily ovarian cancer trial intelligence include:

• Gynecologic oncology pharma teams tracking competitor pipeline activity across FRα, PARP, and ADC programs
• Clinical development leaders at mid-size biotech companies with Phase 1–2 programs needing competitive landscape updates
• Medical affairs professionals at sponsors with approved products monitoring the competitive trial environment
• Healthcare investors and analysts covering the gynecologic oncology space
• Clinical trial coordinators and CROs monitoring competing enrollment for patient recruitment strategy

What a daily digest covers

Each morning's email digest includes trials that became newly posted or received material updates in the prior 24 hours. For ovarian cancer specifically, a typical digest includes:

• New Phase 1/2 trials opened for enrollment with sponsor and site information
• Phase 3 trial status changes (enrollment complete, primary endpoint reported)
• Protocol amendments that materially change eligibility criteria
• New arms added to ongoing basket or umbrella trials
• New sites opened for currently enrolling trials

How DataLookout monitors ovarian cancer trials

DataLookout queries ClinicalTrials.gov daily using ovarian cancer condition terms and related MeSH headings. The pipeline collects all trials matching your keywords, compares them to the prior day's snapshot, and extracts studies that are new or have received updates. The digest strips noise — administrative updates, minor site additions — and surfaces only changes that are likely relevant to your work.

You can configure your alert to cover all ovarian cancer trials broadly, or narrow to specific mechanisms (PARP, ADC, immunotherapy), phases (Phase 2/3 only), or sponsor types (industry-sponsored only, NIH-sponsored, or all).

Related clinical trial monitors

Professionals working in gynecologic oncology often monitor multiple related areas:

• Breast cancer clinical trials — overlapping ADC and PARP programs, shared HER2 and BRCA biology
• Pancreatic cancer clinical trials — KRAS-targeted programs with relevance to mucinous ovarian cancer
• Melanoma clinical trials — immunotherapy combination strategies with relevance across solid tumors